The revenue increase for the fourth quarter of 2022 was primarily due to $46.1 million in collaboration revenue related to our agreements with GSK and Pfizer. The forward-looking statements included in this press release represent Speros views as of the date of this press release. Jamie comes to Spero Therapeutics from uniQure Therapeutics where he served as CHRO, and Intarcia Therapeutics, where he served as Vice President, Human Resources. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13736217, or click on this link and request a return call. Get 30 Days of MarketBeat All Access Free, By creating a free account, you agree to our, 3 Dividend Stocks That Still Make Sense in 2023, Stock market today: World shares retreat after China reports weaker than expected growth in 2Q, China's economy misses growth forecasts, raising the odds of more support for its tepid recovery, United Health Stock Is Flying, It May Only Be The Beginning, Investors Like Adobe's Potential To Leverage Generative AI, Turkish President Erdogan heads to Persian Gulf states seeking funds for ailing economy, Joby Aviation Stock Moves Higher With Catalyst For More Growth. Change-0.02 % Change-1.30% Negative As of Jul 12 2023. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Laser breakthrough could send stock soaring 2,467%. SPRO Earnings Date and Information. Speros culture is one that emphasizes servant leadership, or putting ego aside and working for the benefit of the team and our patients, and values our colleagues opinions and celebrates accomplishments in service of patients. In this role he was responsible for the all business activities in International markets outside USA.Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. Spero Therapeutics (NASDAQ:SPRO) has a recorded annual revenue of $53.51 million. Spero Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). Spero and the FDA also achieved alignment on key components of the proposed pivotal Phase 3 trial design, which will be subject to a Special Protocol Assessment (SPA) agreement. In both roles, he was responsible for all aspects of human resources including talent acquisition, total rewards, and people technology and operations. Oops! Spero Therapeutics Announces Lifting of FDA Clinical Trial - GlobeNewswire 11,459,357. Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical stage drug discovery, development and manufacturing company. Spero professionals share our companys ambitious focus on addressing unmet needs in infectious disease and helping to find solutions to treat patients who suffer from these infections. We expect to submit an IND application to the FDA to support this Phase 2 trial in the fourth quarter of this year. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. During the meeting, the agency indicated that positive results from a single additional Phase 3 clinical trial supported by confirmatory nonclinical evidence of efficacy could be sufficient to support the approval of tebipenem HBr for the treatment of cUTI, including pyelonephritis for a limited use indication. The event featured Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School, a patient with NTM-PD, affiliated with a local chapter of NTMir, the national NTM patient advocacy organization, and Kamal Hamed, Speros CMO, who detailed the various attributes and pharmacological profile of SPR720. Real-time Estimate Tradegate - 10:25:24 2023 . Spero Therapeutics Receives Complete Response Letter from - GlobeNewswire Kamal holds an MD degree from the American University of Beirut, an MPH degree from the Johns Hopkins University, and an MBA degree from the University of South Florida. Speros lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in cUTI, including pyelonephritis. Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) CAMBRIDGE, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset . Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections. Spero Therapeutics (NASDAQ:SPRO) has a recorded net income of -$46.42 million. Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health, As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Spero Therapeutics Announces Third Quarter 2022 Operating - GlobeNewswire For more information, visit https://sperotherapeutics.com. Did Spero Therapeutics beat their earnings estimates last quarter? Source: Bukhta Yurii / Shutterstock.com Let's get into. Prior to his time at Lysovant, Dr. Hamed was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. Shares of Spero Therapeutics Inc. SPRO, +1.08% plummeted 68.4% toward a record low in premarket trading Tuesday, after the Massachusetts-based biopharmaceutical company said it is . Be Humble. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc., where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertexs entire portfolio and operations across more than 30 countries. AboutSperoTherapeuticsSpero Therapeuticsis a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases. Based in New Jersey, Catalent provides advanced delivery technologies and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. These forward-looking statements should not be relied upon as representing Speros views as of any datesubsequent tothe date of this press release. Using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. With around USD 5 billion in sales in 2020, Swiss-based Lonza has consolidated as a titan in the CDMO industry. Based on its current operating plans, Spero believes that its cash and cash equivalents, together with other non-dilutive funding commitments, will be sufficient to fund its operating expenses and capital expenditure requirements beyond 2024. September 15, 2022 16:05 ET Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Novel Treatment Development For Multi-Drug - Spero Therapeutics In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. In some cases, forward-looking statements can be identified by terms such as may, will, should, expect, plan, aim, anticipate, could, intent, target, project, contemplate, believe, estimate, predict, potential or continue or the negative of these terms or other similar expressions. Dr. Hamed commented, The opportunity to lead the development of Speros pipeline programs is exciting, as each targets an urgent unmet need in the antibiotic space. The chart below shows up to four years of a company's earnings history. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Our daily ratings and market update email newsletter. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. We look forward to learning more about you and your career interests in Spero Therapeutics! Forward Looking StatementsThis press release may contain forward-looking statements. Spero Therapeutics last released its quarterly earnings data on May 11th, 2023. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the potential to generate transformative responses in patients with solid tumors. Investor Contact: IR@sperotherapeutics.com Media Contact Media@sperotherapeutics.com Business Development Contact: BD@sperotherapeutics.com General Inquires: info@sperotherapeutics.com or at 857-242-1600 Office Location: 675 Massachusetts Avenue 14th Floor Cambridge, MA 02139 Contact Us Fill out the form to get in touch! However, while Spero may elect to update these forward-looking statements at somepoint in the future, it specifically disclaims any obligation to do so. CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided a business update. You have already added five stocks to your watchlist. There is a desperate need to find a new suite of drugs that can arrest NTM infection and prevent the lung damage that infection causes. Iceni Court, Delft Way, 75N93021C00022. Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases. The conference call will also be webcast live and a link to the webcast can be accessed here and on Spero Therapeutics' website at www.sperotherapeutics.com in the "Investors and Media" section under "Events and Presentations." Previously, Dr. Vink was employed at Cubist Pharmaceuticals. Department of Defense Select SPR206 studies are supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. CLSA members have raised $1M with a goal of sustaining 3-year commitments of $1M annually for Racial & Social Equity InitiativeWe Commit To Change, 111 Oyster Point BlvdSouth San Francisco, CA 94080Phone: 650-881-6500Fax: 650-553-9659, General Inquires: general@sutrobio.comBusiness Inquires: busdev@sutrobio.comInvestor Relations Inquires: IR@sutrobio.comCareers: jobs@sutrobio.com, Take a Closer Look at the Promise of Our iADC Next-Gen Technology, Clinical / Scientific Presentation & Publication Highlights. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Spero Therapeutics Announces FDA Acceptance and Priority Review of New We look forward to working with the FDA during the NDA review process as we prepare for tebipenem HBrs anticipated launch in the second half of 2022.. CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and. Ankit has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Studies. Our world-class team of biotechnology and biopharmaceutical experts embraces the Italian word spero which means hope. It is our mission to bring hope to patients and families of loved ones suffering from serious infections. BlackRock Kicks Off Financials Earnings Season, Gauge To Markets, JPMorgan Chase Is In Reversal But Dont Chase It Higher, Nikola's Stock Surges On New Deals And Rising Short Interest, Get Your Cash Out of U.S. Banks Immediately, Skip Charts & View Estimated and Actual Earnings Data. Spero Therapeutics ( NASDAQ: SPRO) has announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer. Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates